Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized
That said, there are a couple of important caveats
The December 2024 FDA approval for moderate-to-severe OSA created a new coverage pathway
The regulatory landscape for peptides continues evolving
The primary concern with compounded medications is quality control and effectiveness
699 950 + 999 978 1 270 1 724 780 570 790 899 1 209 890 2 155 511 1 460 1 209 1 300 869 1 740 978 690 1 572 750 820 1 006 784 + 1 119 590
US$ 29.89
US$ 25.98
US$ 23.60
